Drug intelligence / Profile preview

scFv-35

Development stage: Preclinical
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

scFv-35 is a single-chain variable fragment (scFv) designed to inhibit the complement system. Its primary therapeutic goal is to target the neuromuscular junction (NMJ) to prevent complement-mediated damage. This drug is being investigated as a potential treatment for myasthenia gravis (MG), an autoimmune disorder characterized by pathology at the NMJ involving complement activation.

Targets

Complement (Complement system)

Beyond the preview

Go deeper on scFv-35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on scFv-35.

Explore the full profile